News

The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2

Vertex Pharmaceuticals (NASDAQ:VRTX) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I’ll be watching whether CASGEVY and JOURNAVX stay on pace for management’s $500 million non-CF revenue target. Diversification Picks Up Speed After a Raised Outlook Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus. Adjusted EPS […]

Yahoo·09:45VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...

Yahoo·23:19VRTX▼−0.0%

What Vertex Pharmaceuticals Holders Bought Into

If Vertex Pharmaceuticals was on your watchlist rather than in your portfolio, the return may sting. Investors who held Vertex Pharmaceuticals over the past year are up 24.3%, including dividends. That period included upbeat cystic fibrosis launches, new gene therapy approvals and a planned US$10b move into endocrinology, yet none of that was visible at the October 2025 starting line. The real question is whether early conviction around diversified gene editing and new therapies was the key...

Yahoo

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

Vertex is expanding beyond its cystic fibrosis franchise.

Yahoo·15:29VRTX▼−0.0%

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

SeekingAlpha·23:27VRTX▼−0.0%

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm

Yahoo·23:02VRTX▼−0.0%

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow

2026-10-23. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.

SeekingAlpha·17:31VRTX▼−0.0%

Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?

For questions about this article or underlying research, email help@trefis.com.

Yahoo·13:29VRTX▼−0.0%

Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s

Benzinga·09:43VRTX▼−0.0%

Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now, with newer treatments entering the market and its acquisition of Crinetics Pharmaceuticals completed, the company is working to establish additional sources of growth. The stock closed at $510.08 on October 9, with a forward P/E of 24.10, according to the […]

Yahoo·11:19VRTX▼−0.0%

Why Should You Think About Vertex Differently Now?

Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own, and the company's priorities have changed. During its fiscal Q3 2024 call, management said it expected sustained revenue growth in cystic fibrosis (CF) over the short, medium and long term. The latest call still called CF a franchise with sustained growth, but it spent more time

Yahoo·20:56VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.

Yahoo·16:50VRTX▼0.0%

What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders

Vertex Pharmaceuticals recently presented interim data from its ALYFTREK regimen in children aged 2 to 5 with cystic fibrosis, showing restored exocrine pancreatic function in some patients and enabling a portion to stop lifelong pancreatic enzyme replacement therapy. The reported recovery of pancreatic function in a condition long viewed as permanently damaging points to a potential shift in how early cystic fibrosis treatment might affect long term organ health and future standard of care...

Yahoo·11:12VRTX▼−0.0%

Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data

Vertex Pharmaceuticals has rewarded long term shareholders, and that kind of track record naturally raises the question of whether today's valuation is still grounded in the cash the business can produce. With fresh data on its cystic fibrosis pipeline and gene therapy progress in the spotlight, investors are increasingly asking how much of that story is already priced into Vertex's cash flows. Over the past 5 years, Vertex has delivered a share price gain of 172.3%. That puts a lot of...

Yahoo·19:10VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX) Pancreatic Function Data Puts Its Undervalued Narrative In Focus

Vertex Pharmaceuticals (VRTX) stepped into the spotlight after new interim ALYFTREK data at the North American Cystic Fibrosis Conference suggested some young children regained pancreatic function and were able to stop enzyme replacement therapy. For context, Vertex Pharmaceuticals has given investors a mixed near term ride, with the 1 day share price return down 1.77% and the 30 day share price return down 2.63%, yet the 90 day share price return up 2.90% and the year to date share price...

Yahoo

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Yahoo·08:00VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

Yahoo·17:00VRTX▼−0.0%

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

Vertex Pharmaceuticals is showing that it isn't a one-trick pony.

Yahoo·11:01VRTX▼−0.0%

What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release

Vertex Pharmaceuticals is set to report its Q3 results next month, with analysts anticipating single-digit EPS growth alongside continued earnings growth.

Yahoo·08:44VRTX▼−0.0%

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.

Yahoo·08:37VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.

Yahoo·16:50VRTX▼−0.0%

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

BOSTON, October 09, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib

Yahoo·13:15VRTX0.0%

Is Vertex Stock Worth More Than Its Competitors?

Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.

Yahoo·11:36VRTX▼−0.0%

Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented -Vertex

Benzinga·09:17VRTX0.0%

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Yahoo·08:00VRTX▼−0.0%

Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project

Desktop study will use existing geological, geophysical and well data to assess natural hydrogen and helium potentialVANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has commissioned Lonquist Field Service (Canada), ULC (“Lonquist”) to conduct a desktop geological study to evaluate the potential for naturally occurring hydrogen and helium at its 100%-owned Robinsons Ri

Yahoo·08:00VRTX0.0%

2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Yahoo·05:55

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets

Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]

Yahoo·22:40VRTX▼−0.0%

Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks

Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select biotechnology stocks with more reasonable finances can draw interest. This article breaks down three biotech stocks from a curated screener that aims to balance high upside with some measure of financial discipline. The stocks covered below are just a small...

Yahoo·18:07VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.

Yahoo·17:00VRTX0.0%

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.

Yahoo·15:17VRTX▼−0.0%

$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals has a market

Benzinga·12:15VRTX▼−0.0%

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.

This biotech player is firing on all cylinders.

Yahoo·05:30VRTX▼−0.0%

Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade

Vertex Pharmaceuticals commands a dominant, highly profitable cystic fibrosis franchise. Find out why VRTX stock is downgraded to a hold.

SeekingAlpha·04:30VRTX▼−0.0%

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]

Yahoo·20:37VRTX▼−0.0%

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.

Benzinga·10:00VRTX▼0.0%

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.

Yahoo·16:50VRTX▼−0.0%

Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

Yahoo·10:27VRTX▼−0.0%

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Yahoo·09:02VRTX▼−0.0%

Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues

Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...

Yahoo·23:23VRTX▼−0.0%

Vertex Posts Positive Phase II Data on Kidney Disease Drug

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.

Yahoo·12:08VRTX0.0%

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race

Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy Market Autologous Hematopoietic Stem Cell Gene Therapy Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Autologous Hematopoietic Stem Cell Gene Therapy Mar

Yahoo·06:49VRTX▼−0.0%

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

Yahoo·13:39VRTX▼−0.0%

Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

Yahoo·12:46VRTX▼−0.0%

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

Yahoo·10:17

Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026

CKD drug development is shifting toward disease-modifying and cardiorenal therapies, creating opportunities in early detection, high-risk screening, combinations and licensingDublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of more than 90 companies and over 100 marketed and investigational drugs within the global chronic

Yahoo·09:31

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

BOSTON, September 22, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.

Yahoo·08:00VRTX▼−0.0%

2 Reasons to Like VRTX (and 1 Not So Much)

Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.9% to $514.18 per share while the index has gained 14%.

Yahoo·13:52VRTX▼−0.0%

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

This company has had plenty of setbacks in recent years, but it generally bounces back.

Yahoo·13:20

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Yahoo·23:20

Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Global Strategic Minerals Corp. (the “Vendor”), pursuant to which the Company will acquire (the “Transaction”) the Purchased Assets (as defined below) comprising the Meadows Project (the “Project”) located in west-central Saskatchewan nea

Yahoo·17:30VRTX▼−0.0%

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout

Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.

Yahoo·16:09

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.

Yahoo·11:26

Will Vertex’s (VRTX) New CFO Elevation and Digital Focus Reframe Its Capital Allocation Narrative?

In August 2026, Vertex Pharmaceuticals announced that Senior Vice President of Finance Jonathan Poole will become Executive Vice President and Chief Financial Officer on January 1, 2027, while Charles F. Wagner Jr. remains Executive Vice President and Chief Operating Officer. This internal promotion, paired with Vertex’s increased external visibility through forums such as the Boston C-Level Technology Leadership Summit, highlights how the company is elevating both its financial leadership...

Yahoo·15:17VRTX▼−0.0%

Vertex Pharmaceuticals (VRTX), Why Is It Getting Fresh Attention Now?

Vertex Pharmaceuticals (VRTX) has been in focus after presenting at the 18th Annual Boston C-Level Technology Leadership Summit on September 10, where its Chief Digital and Information Officer outlined the group’s technology priorities. Recent trading has been choppy for Vertex Pharmaceuticals, with the share price falling 4.9% over the past week but still showing a 14.6% 90 day share price return and a 32.1% 1 year total shareholder return. This points to momentum that has built over a...

Yahoo